What ISCT Says About the Landmark FDA Approval of Allogeneic MSCs
The recent FDA approval of Mesoblast’s Ryoncil™, an allogeneic bone-marrow mesenchymal stromal cell (MSC) therapy, marks a significant milestone in regenerative medicine and cell therapy. This long-anticipated decision provides new hope for patients with steroid-refractory acute Graft-versus-Host Disease (GvHD) and sets a regulatory precedent for future MSC-based therapies worldwide. The International Society for Cell & [...]